McKesson Corporation (MCK) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in McKesson (MCK) by buying shares or fractional shares at any major US broker, through a healthcare or S&P 500 ETF that holds it, or as one holding in a thematic basket. McKesson is one of the three companies that dominate US pharmaceutical distribution, moving drugs from manufacturers to pharmacies, hospitals, and clinics at enormous volume. The single biggest thing to understand is that distribution itself is a razor-thin-margin, high-volume business: McKesson earns pennies on each dollar of the hundreds of billions it moves, so the real profit and growth story increasingly comes from higher-margin specialty, oncology, and prescription-technology services layered on top of that logistics backbone.
MCK stock price
As of 2026-07-14, McKesson Corporation (MCK) last closed at $805.89, up 12.6% over the past year. Over the past 52 weeks it has traded between $659.01 and $995.69.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or McKesson Corporation's investor relations page. Walnut is informational, not investment advice.
What does McKesson Corporation (MCK) do?
McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. In fiscal 2026 the company reported roughly $337 billion in revenue, the bulk of it from its North American Pharmaceutical segment, which sources, warehouses, and delivers branded, generic, and specialty medicines to pharmacies, health systems, and providers. Because distribution is a scale game with very low margins, McKesson competes on logistics efficiency, breadth of contracts, and reliability rather than pricing power on the drugs themselves.
The more interesting part of the story is McKesson's shift toward higher-margin services built on that backbone. Its Oncology and Multispecialty segment (including the US Oncology Network, group purchasing, specialty distribution, and provider technology) and its Prescription Technology Solutions segment generate meaningfully better margins than raw distribution. In 2026 the company was also moving to separate its lower-margin Medical-Surgical Solutions business, completing initial financing steps toward that split, to focus the core on pharmaceutical distribution plus oncology and biopharma services. Management repeatedly raised full-year adjusted EPS guidance through fiscal 2026, and the company returns substantial cash through buybacks and a growing dividend.
What's driving McKesson Corporation (MCK)?
1. Defensive, volume-driven distribution core
Drug distribution is a non-discretionary business: prescriptions get filled in good economies and bad, and an aging population plus rising prescription volumes provide a slow, steady tailwind. McKesson's scale in the Big Three oligopoly gives it durable contracts with large retail chains and health systems. This makes the core earnings stream relatively defensive, even if each dollar of revenue carries very thin margins.
2. Specialty and oncology services mix-shift
The bigger profit lever is McKesson's push up the value chain into specialty drug distribution, the US Oncology Network, biopharma and provider services, and cell-and-gene-therapy logistics. These carry higher margins than commodity distribution and are growing faster. As this mix grows, blended profitability can improve even though the reported top line is dominated by low-margin volume.
3. Prescription Technology Solutions
McKesson's Prescription Technology Solutions segment connects manufacturers, pharmacies, and patients with access, affordability, and adherence tools, and it earns far higher margins than distribution on a much smaller revenue base. Demand for patient-access programs (co-pay support, prior authorization, specialty onboarding) rises with the growth of expensive specialty and biologic drugs, giving this unit a structural growth runway.
4. Capital returns and portfolio focus
McKesson generates strong operating cash flow and has consistently returned it through large share repurchases and a rising dividend, which shrinks the share count and supports per-share earnings growth. The planned separation of the Medical-Surgical Solutions business is meant to sharpen the portfolio around pharmaceutical distribution plus oncology and biopharma services, potentially improving the growth and margin profile of what remains.
What are the risks to McKesson Corporation (MCK)?
The central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. Customer concentration is real, with a few very large retail-pharmacy customers representing a big share of revenue, giving those partners negotiating leverage. Drug-pricing politics and policy (Medicare negotiation, PBM reform, importation proposals) create ongoing regulatory uncertainty. McKesson also carries a legacy of multibillion-dollar opioid-distribution settlements, and future litigation or regulatory action remains a tail risk. Execution on the Medical-Surgical separation and on integrating oncology and specialty acquisitions adds transition risk on top of the steady core.
How is McKesson Corporation (MCK) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see McKesson Corporation's investor relations page or your broker.
- Revenue (FY2026): ~$337 billion, the vast majority from North American pharmaceutical distribution (approximate; verify live)
- Segment profit mix: North American Pharmaceutical ~$3.5B adjusted operating profit; Oncology & Multispecialty ~$1.4B; Prescription Technology ~$1.1B (approximate)
- Margin profile: Very low overall (low-single-digit operating margin) because distribution dominates revenue; services segments carry much higher margins
- Earnings trend: Management raised full-year adjusted EPS guidance multiple times through fiscal 2026 (qualitative; confirm latest figures)
- Capital returns: Ongoing large share buybacks plus a growing dividend; historically a modest yield relative to price
- Valuation framing: Typically valued on adjusted EPS and free cash flow rather than revenue multiples, given the thin-margin model; check the current P/E live
All figures are approximate, tied to the asOf date, and blend fiscal-year and quarterly disclosures; verify live numbers before acting. Note McKesson reports on a fiscal year ending in March, so "fiscal 2026" spans calendar 2025 into early 2026. Because distribution revenue is enormous but low-margin, revenue-based multiples are misleading here: analysts focus on adjusted EPS growth, free cash flow, and the mix-shift toward higher-margin services.
Who competes with McKesson Corporation (MCK)?
The Big Three drug distributors
McKesson's direct rivals are Cencora (formerly AmerisourceBergen) and Cardinal Health. Together the three control the large majority of US pharmaceutical distribution, an oligopoly built on scale and logistics. All three are pushing into higher-margin specialty and oncology ecosystems, so competition increasingly plays out in services rather than raw distribution.
Specialty, oncology, and GPO players
In oncology and specialty services McKesson (via the US Oncology Network) competes with Cardinal Health's Navista, Cencora's oncology and specialty units, and group purchasing and practice-management organizations. Pharmacy benefit managers and integrated payers like CVS Health, Cigna's Express Scripts, and UnitedHealth's Optum also shape drug-channel economics that affect distributors.
Medical-surgical and adjacent distribution
In medical-surgical products and healthcare supply chain, McKesson's separating Medical-Surgical business competes with Cardinal Health, Owens & Minor, Henry Schein, and Patterson. These are distinct markets from pharmaceutical distribution but part of the broader healthcare-logistics landscape McKesson operates across.
How to invest in McKesson Corporation (MCK)
There are three common ways to get MCK exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so MCK sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where MCK fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on McKesson Corporation (MCK)
McKesson is a defensive, cash-generative logistics giant at the center of US drug distribution, with a growing higher-margin oncology and specialty-services layer. The bet is steady volume-driven earnings and buybacks, tempered by wafer-thin distribution margins, opioid-settlement history, and drug-pricing policy risk.
Build a basket around MCK with Walnut
Use McKesson Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MCK a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a defensive, cash-generative distribution franchise with rising higher-margin oncology and specialty services, steady buybacks, and repeated guidance raises. The bear case is razor-thin distribution margins, heavy customer concentration, drug-pricing policy risk, and a legacy of opioid-settlement liabilities. Weigh both against your own portfolio.
What does McKesson actually do?
+
McKesson is a pharmaceutical distributor and healthcare-services company. Its core business buys drugs from manufacturers and delivers them to pharmacies, hospitals, and clinics at massive scale. On top of that logistics backbone it runs higher-margin businesses in specialty and oncology services, group purchasing, and prescription-access technology. It does not manufacture the drugs it distributes.
Why are McKesson's profit margins so low?
+
Distribution is a high-volume, low-margin business. McKesson earns only a small fraction of each dollar of drugs it moves, mainly through fees and buy-side efficiencies rather than markups on branded medicines. That is why its roughly $337 billion of revenue translates into comparatively modest operating profit, and why the mix-shift toward higher-margin services matters so much to the story.
Who are McKesson's biggest competitors?
+
Its main rivals are the other two members of the Big Three drug distributors, Cencora (formerly AmerisourceBergen) and Cardinal Health. In oncology and specialty services it also competes with Cardinal's Navista and Cencora's specialty units, and pharmacy benefit managers and integrated payers like CVS, Express Scripts, and Optum shape the broader drug-channel economics.
Why is McKesson separating its Medical-Surgical business?
+
In 2026 McKesson announced plans to separate its lower-margin Medical-Surgical Solutions segment and completed initial financing steps toward the split. The goal is to focus the remaining company on pharmaceutical distribution plus higher-growth oncology and biopharma services, which could sharpen its margin and growth profile. Separations carry execution and transition risk, so watch how it unfolds.
Does McKesson pay a dividend?
+
McKesson has a long history of paying and steadily raising its dividend, though the yield tends to be modest relative to the share price because management returns most cash through large share buybacks. Income is not the primary reason most investors hold the stock. Always check the latest declared dividend and yield before assuming any payout.
How does drug-pricing policy affect McKesson?
+
Policy changes such as Medicare drug-price negotiation, pharmacy-benefit-manager reform, and importation proposals can reshape the economics of the drug channel. As a distributor, McKesson is somewhat insulated because it earns fees on volume rather than on drug prices, but major shifts in how drugs are priced, reimbursed, or routed could still affect its contracts and margins.
How can I get exposure to McKesson through an ETF?
+
MCK is a large-cap S&P 500 component and appears in many broad-market, healthcare, and healthcare-distribution ETFs. Fund exposure spreads single-stock risk across many holdings but dilutes how much any McKesson move affects you. Always check a fund's holdings and weighting before assuming meaningful exposure to McKesson specifically.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with McKesson Corporation's investor relations page or your broker before making investment decisions.